CRP and myocardial infarction: In a pre-specified secondary analysis of this trial of 10,061 people with previous myocardial infarction and high C-reactive protein (CRP), treatment with the interleukin-1β inhibitor canakinumab substantially reduced circulating inflammatory markers, but did not significantly reduce risk of new-onset diabetes in participants without diabetes at recruitment, or improve glycaemia in participants with diabetes [20].